title: Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application.
authors.affiliation: Haemato-Oncology Research Unit, Division of Cancer Therapeutics, Molecular Pathology and Clinical Studies, Institute of Cancer Research, Sutton, England.
authors.forename: L I
authors.initials: LI
authors.lastname: Aronson
authors.forename: E L
authors.initials: EL
authors.lastname: Davenport
authors.forename: F
authors.identifier: 0000000337856868
authors.initials: F
authors.lastname: Mirabella
authors.forename: G J
authors.initials: GJ
authors.lastname: Morgan
authors.forename: F E
authors.initials: FE
authors.lastname: Davies
mesh_terms: D001343:Autophagy; D006801:Humans; D009101:Multiple Myeloma / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000081082:Phosphoinositide-3 Kinase Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D046988:Proteasome Endopeptidase Complex